FDA Approves Abraxane
Abraxane American Pharmaceutical Partners, Inc. / American Bioscience, Inc. - Treatment for Metastatic Breast Cancer
Abraxane, consisting of albumin-bound paclitaxel nanoparticles, is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.Posted: January 2005
Related articles
- FDA Approves Abraxane for Late-Stage Pancreatic Cancer - September 6, 2013
- FDA Approves Abraxane for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer - October 12, 2012
- American Pharmaceutical Partners and American BioScience Announce FDA Acceptance of New Drug Application of Abraxane for the Treatment of Metastatic Breast Cancer - May 10, 2004
- American Pharmaceutical Partners and American BioScience Announce Filing of a New Drug Application for FDA Approval of Abraxane for the Treatment of Metastatic Breast Cancer - March 8, 2004
Abraxane (paclitaxel protein-bound) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
